The India Diabetes Devices Market is expected to witness growth from $413 Mn in 2022 to $899 Mn in 2030 with a CAGR of 10.20% for the forecasted year 2022-2030. In 2020, over 77 million adults in India have diabetes, making it one of the countries with the highest prevalence of the illness. The nation's demand for diabetes devices is anticipated to be driven by the high incidence of diabetes. The market is segmented by type and by the end user. Some key players in this market include Poly Medicure, Biosurge Healthcare, Johnson & Johnson, Medtronic, Roche, Ascensia Diabetes Care and Dexcom.
The India Cardiac Surgery Instruments Market is expected to witness growth from $38 Mn in 2022 to $78 Mn in 2030 with a CAGR of 9.60% for the forecasted year 2022-2030. India has a significant incidence and prevalence of Cardiovascular Diseases (CVD), including coronary artery disease, heart failure, and hypertension. The demand for cardiac surgery equipment in the Indian healthcare industry is anticipated to rise as CVD prevalence in that country continues to rise. The market is segmented by type, application and by end user. Some key players in this market include Becton Dickinson, GPC Medical, Sahajanand Medical Technologies, LivaNova, B. Braun, Medline Industries, KLS Martin, and STILLE.
India's cardiovascular disease therapeutics market is projected to grow from $2.95 Bn in 2022 to $6.44 Bn in 2030 with a CAGR of 10.22% for the year 2022-2030. The changing lifestyles leading to the increased prevalence of hypertension and other cardiovascular diseases are the major market drivers. The India cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Aventis Pharma, Viridis Biopharma, and Bayer are the major players in the India cardiovascular disease therapeutics market.
India anti-aging therapeutics market is expected to witness growth from $11 Mn in 2022 to $46 Mn in 2030 with a CAGR of 19.53% for the year 2022-2030. The growth from the baby boomer population to the middle age population in India and their subsequent demand for ant-aging products for a more youthful appearance are the major market drivers. The India anti-aging therapeutics market is segmented by product, treatment, target group, type of aging, type of molecules, mechanism of action, ingredient, and by distribution channel. Glenmark, Navitor Pharmaceuticals, and NeuroTrack are some of the key players in the market.
India's Artificial Intelligence (AI) in the healthcare market is projected to grow from $0.13 Bn in 2022 to $2.92 Bn by 2030, registering a CAGR of 48.22% during the forecast period of 2022-2030. The market will be driven by Increasing healthcare demands due to the rising population, government support, and initiatives. The market is segmented by healthcare components & by healthcare applications. Some of the major players include IBM Watson Health, Qure.ai & PharmEasy.
The Indian healthcare insurance market is projected to grow from $36.85 Bn in 2022 to $82.5 Bn by 2030, registering a CAGR of 10.6% during the forecast period of 2022 - 2030. The main factors driving the growth would be growing awareness, technological advancements, increased competition and government Initiatives. The market is segmented by the component, provider, coverage, by health insurance plans and end-user. Some of the major players include HDFC ERGO, Star Health and Allied Insurance, Niva Bupa, ICICI Lombard and Care Health Insurance.
The India Biosimilars market size was valued at $349 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 25.2% from 2022 to 2030 and will reach $2108 Mn in 2030. The market is segmented by product type and indication type. The Indian Biosimilars market will grow as India's biosimilar market is driven by its cost-effective manufacturing capabilities. The key market players are Biocon Ltd (IND), Intas Pharmaceuticals Ltd (IND), Dr. Reddy's Laboratories Ltd (IND), Reliance Life Sciences Pvt. Ltd (IND), Zydus Cadila Healthcare Ltd (IND), Lupin Limited (IND)and others.
The India healthcare claims management market is projected to grow from $485.57 Mn in 2022 to $3163.92 Mn by 2030, registering a CAGR of 26.4% during the forecast period of 2022 - 2030. The main factors driving the growth would be growing health insurance penetration, increasing adoption of digital technology, rising healthcare frauds and government initiatives. The market is segmented by component, type, delivery mode and by end-user. Some of the major players include Wipro, Infosys, Tech Mahindra, Accenture and eClinicalWorks.
India's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is expected to grow from $538 Mn in 2022 to $1,195 Mn in 2030 with a CAGR of 10.5% for the year 2022-30. With a larger prevalence of ADHD in India than that globally, the ADHD therapeutics market in India has a lot of potential. The India ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Actiza Pharmaceutical, Ayursun Pharma, and Eli Lily are some of the key players in the market.
By 2030, it is anticipated that the India Liver Disease Therapeutics market will reach a value of $818 Mn from $420 Mn in 2022, growing at a CAGR of 8.7% during 2022-2030. Liver Disease Therapeutics in India is dominated by domestic pharmaceutical companies such as Dr. Reddy's Laboratories, Cadila Healthcare, and Sun Pharmaceutical. The Liver Disease Therapeutics market in India is segmented into different types of disease and different therapy types. Some of the significant factors affecting the India Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.
The India home healthcare market was valued at $179 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 6.40% from 2022 to 2030 and will reach $295 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, The increased prevalence of chronic ailments. The market is segmented by equipment outlook and by services. Some key players in this market are Apollo Homecare, Portea Medical, India Home Hea lth Care, Healthcare at Home, Care24.
The India Telemedicine market was valued at $1.10 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 21.2% from 2022 to 2030 and will reach $5.15 Bn in 2030. One of the main reasons propelling the growth of this market is the advent of advanced technologies and rising cases of chronic and lifestyle-related diseases. The market is segmented by end-user, product type, and Delivery mode. Some key players in this market are Apollo Telehealth Services, Practo Technologies, 1mg Technologies, and Clove Dental.
The India dental care market was valued at $653 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 9.40% from 2022 to 2030 and will reach $1339 Mn in 2030. One of the main reasons propelling the growth of this market is the rising knowledge and awareness among individuals regarding dental aids and various treatments that aim to improve personal health and hygiene. Some key players in this market are Clove Dental, 3M, Dentsply Sirona, GE Healthcare, Philips Healthcare.
India's oncology clinical trials market is projected to grow from $230.1 Mn in 2022 to $441.8 Mn by 2030, registering a CAGR of 8.5% during the forecast period of 2022-30. The market will be driven by the rising prevalence of Oncological disorders, the availability of a large patient pool with various genetic profiles, and low-cost clinical trials. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cadila Healthcare Ltd. & Cipla Ltd.
The India Oral Care market was valued at $641 Mn in 2022 and is estimated to expand at a CAGR of 9.2% from 2022 to 2030 and will reach $1295 Mn in 2030. One of the main reasons propelling the growth of this market is Increasing urbanization, aging population. The market is segmented by type, drug and distribution channel. Some key players in this market are Dabur India, Patanjali Ayurved, Colgate-Palmolive, Himalaya Wellness, Vicco Laboratories, Procter & Gamble, Baidyanath Ayurveda, Unilever among others.
The India Multiple Myeloma Therapeutics Market was valued at $152 Mn in 2022 and is estimated to expand at a CAGR of 7.5% from 2022 to 2030 and will reach $271 Mn in 2030. One of the main reasons propelling the growth of this Market is increase in prevelance, Increasing awareness and screening programs. The Market is segmented by type, drug and distribution channel. Some key players in this Market are Natco Pharma, Cipla, Hetero Drugs, Biocon, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Lupin, Cadila Healthcare and others.
The India diabetes drugs market size was valued at $1.12 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 9.10% from 2022 to 2030 and will reach $2.25 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The India diabetes drug market will grow because India’s high prevalence of diabetes, the increasing demand for newer, more effective treatments, and the growing focus on prevention and early intervention. The key market players are Biocon (IND), Sun Pharma (IND), Lupin (IND), Cadila Healthcare (IND), Dr. Reddy's Laboratories (IND), and others.
The India-connected healthcare market is projected to grow from $1.21 Bn in 2022 to $10.73 Bn by 2030, registering a CAGR of 31.4% during the forecast period of 2022 - 2030. The main factors driving the growth would be increasing healthcare needs, growing smartphone penetration, increasing healthcare spending and government initiatives. The market is segmented by type, function and by application. Some of the major players include Practo, HeyDoc, Omron Healthcare, TATA 1mg, Philips Healthcare, GE Healthcare, Cisco Systems and IBM.
India artificial intelligence (AI) in medical Imaging market size was valued at $27 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 38.4% from 2022 to 2030 and will reach $367 Mn. The market is segmented by AI technology, solution, modality, application, and end User. Due to developments in AI and machine learning algorithms that are enabling the creation of more precise and effective medical imaging software, the India Artificial Intelligence (AI) in the Medical Imaging market will expand. Some of the key players in this market Niramai Health Analytix, Qure.ai, Predible Health, 4C Medical Technologies, Perfint Healthcare, GE Healthcare, Siemens Healthineers, Philips Healthcare, Fujifilm India and others.
The India Primary Hyperoxaluria (PH) Therapeutics market was valued at $XX Bn in 2022 and is estimated to expand at a CAGR of 7.8% from 2022 to 2030 and will reach $XX Bn in 2030. One of the main reasons propelling the growth of this market is government initiatives, aging population. The market is segmented by diagnostic method, by treatment, and by type. Some key players in this market are Biocon Limited, Sun Pharmaceutical Industries Limited, Lupin Limited, Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, Zydus Cadila, Cipla, Alnylam Pharmaceuticals, among others.
The India Neurology Clinical Trials market is projected to grow from $95.1 Mn in 2022 to $182.7 Mn by 2030, registering a CAGR of 8.5% during the forecast period of 2022 - 2030. The market will be driven by the high prevalence of neurological disorders and the low cost of conducting clinical trials in India. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis, Sun Pharmaceutical Industries & Cadila Healthcare.
The India 3D Printing Medical Devices market size was valued at $54 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 17.8% from 2022 to 2030 and will reach $222 Mn in 2030. The market is segmented by component, application, technology, and end user. The India 3D Printing Medical Devices market will grow as the 3D printing technology allows for the customization of medical devices, which is becoming increasingly important in the healthcare industry. The key market players are 3D Life Prints, Osteo3d, Ayushman3D, Anatomiz3D Medtech, SLM Solutions, EOS, and others.
The India Alzheimer’s disease drugs market was valued at $280 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 11.42% from 2022 to 2030 and will reach $666 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Sun Pharmaceutical Industries, Cipla, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, Alkem Laboratories., Eli Lilly and Company, Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, Pfizer.
The India COPD Therapeutics Market was valued at $332 Mn in 2022 and is estimated to expand at a CAGR of 10.1% from 2022 to 2030 and will reach $717 Mn in 2030. One of the main reasons propelling the growth of this market is increase prevalence rate, government initiative. The market is segmented by Drug class and by distribution channel. Some key players in this market are Cipla, Glenmark Pharmaceuticals, Lupin Limited, Sun Pharmaceutical Industries, Torrent Pharmaceuticals, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, Teva India Limited and others.
By 2030, it is anticipated that the Indian infectious disease therapeutics market will reach a value of $3.84 Bn from $2.18 Bn in 2022, growing at a CAGR of 7.4% during 2022-2030. Infectious Disease Therapeutics in India is dominated by a few domestic pharmaceutical companies such as Cadila Healthcare, Lupin Limited and Sun Pharmaceutical. The Infectious Disease Therapeutics market in India is segmented into different therapeutic areas and different diseases type. The major factors affecting the Indian infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of India.